an-1792
Peptideexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2001 (NCT00021723)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Beta amyloid A4 proteinImmunity, active
APP immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- an-1792
- an-1792
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00021723 | Phase 2 | Sep 1, 2001 | Johnson and Johnson, Wyeth |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2001 |
| Wyeth | For profit | 1 | 0 | 1 | 2001 |
2 organizations
Page 1 / 1